Sillah, Arthur http://orcid.org/0000-0003-1065-6735
Peters, Ulrike
Watson, Nathaniel F.
Tykodi, Scott S.
Hall, Evan T.
Silverman, Allison
Malen, Rachel C.
Thompson, John A.
Lee, Sylvia M.
Bhatia, Shailender
Veatch, Joshua
Warner, Jeannie
Thornton, Timothy
Phipps, Amanda I.
Funding for this research was provided by:
National Institutes of Health (T32CA094880)
pilot funding provided by the Public Health Sciences Division and Immunotherapy Integrated Research Center at the Fred Hutchinson Cancer Research Center
Article History
Received: 20 September 2021
Accepted: 10 January 2022
First Online: 16 January 2022
Declarations
:
: The study protocol was reviewed and approved by the Fred Hutchinson Cancer Research Center, Seattle WA USA.
: All included study participants signed an informed consent.
: All authors gave their consent for publication.
: SB: report advisory board participation (with honorarium) from Genentech, EMD-Serono, Bristol-Myers-Squibb (BMS) and Sanofi-Genzyme, and research funding to his institution (University of Washington) from EMD-Serono, Merck, BMS, Novartis, Incyte, Exicure, Nektar, NantKwest, Oncosec, and Immune Design. All other authors declare there is no conflict of interest.
Free to read: This content has been made available to all.